Pharmaceutical Technology

JUNE 23, 2022

Mpro has become the main focus of intense research and treatment development as it is vital for viral replication. It functions as a molecular scissor by slicing long chains of virus’ polypeptide proteins into smaller component proteins. These smaller segments can subsequently fold and develop to create new virus particles.

Drugs 130

Drugs Protein Genome Genomics 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

The Pharma Data

MARCH 15, 2022

The p53 protein protects our cells from cancer and is an interesting target for cancer treatments. Researchers at Karolinska Institutet in Sweden have now found an unusual way of stabilising the protein and making it more potent. Researchers around the world are therefore trying to develop cancer treatments that in some way target p53.

Protein 52

Protein Research Genetics DNA 52

Drug Discovery World

OCTOBER 2, 2023

X-Chem and the Structural Genomics Consortium (SGC) have entered a collaboration aimed at creating new chemical tools to study human proteins. Under the agreement, X-Chem will use its DEL platform to create datasets for proteins chosen and supplied by the SGC, which will be posted to a public portal to be used for model building.

Genome 52

Genome Genomics Protein DNA 52

Drug Discovery World

AUGUST 21, 2023

SBIR fast-track grant from the NIH to apply its proprietary Multiplexed Assays for the Rational Modulation Of Transcription Factors (MARMOT) platform to their deep learning AI model and accelerate the development of transcription factor drugs. Talus Bio was also awarded a $2.0M The post $4.3

Drugs 98

Drugs Gene Expression Protein Gene 98

Drug Discovery World

SEPTEMBER 27, 2023

HKG Epitherapeutics is a biotechnology company developing novel tools for the early detection of cancer and promoting healthy aging. Embarking on a new era of medicine The advent of genomics has ushered in the era of personalised medicine, enabling us to analyse the genetic makeup of individuals with unprecedented accuracy.

DNA 115

DNA Genetics Gene Medicine 115

Drug Discovery World

MAY 25, 2023

DNA Script: SYNTAX DNA printing platform Using the company’s EDS technology, the SYNTAX platform can synthesise up to 96 highly accurate, ready-to-use DNA oligos with maximum lengths of up to 120nt in less than 24 hours in the laboratory.

Production 52

Production Reagent DNA Drugs 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Within the emerging innovation stage, DNA chips, tissue culturing automation, and mass spectrometry analysis are disruptive technologies that are in the early stages of application and should be tracked closely. Codexis, a protein engineering company, is the leading patent filer.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. T790M loss has been linked to earlier resistance and poorer survival in other cohorts.

Genome 119

Genome Genomics Protein In-Vitro 119

Drug Discovery World

JUNE 22, 2023

In a new paper published in Nature , researchers at the Francis Crick Institute in the UK have outlined the structure and function of a protein complex which is required to repair damaged DNA and protect against cancer. We now understand its crucial role in DNA repair, which explains why mutations can lead to cancer.”

Research 52

Research DNA Protein Gene 52

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

MARCH 2, 2023

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Gene Expression 52

Gene Expression Gene DNA RNA 52

Drug Discovery World

JULY 12, 2022

The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, restoring sensory and motor function after spinal injury.? . Co-author, Dr Richard Tuxworth?from References . 1: Ahmed Z, Tuxworth RI.

DNA 52

DNA Drugs Genome Genomics 52

XTalks

MAY 10, 2022

On Saturday, researchers at the Children’s Hospital of Philadelphia (CHOP) have announced that they developed and launched a new bioinformatics software tool called CancerVar (cancer variant interpretation). Why Was CancerVar Developed? What is CancerVar? This software is implemented in Python and has a user-friendly web server.

Bioinformatics 98

Bioinformatics Development Gene Genome 98

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

FEBRUARY 7, 2024

Professor Jonathan Blackburn, Chief Scientific Officer (CSO) of Sengenics, featured in a sponsored DDW Sitting Down With podcast to discuss the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery chip, and more. He elaborates in the podcast.

Medicine 59

Medicine Protein FDA Approval DNA 59

pharmaphorum

OCTOBER 12, 2022

AstraZeneca has teamed up with DNA sequencing giant Illumina on a new programme that will use artificial intelligence to find new targets for drug discovery by sifting through vast arrays of data generated from “omics” studies.

Genome 64

Genome Genomics DNA Drugs 64

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These systems include human and mouse cell lines, and even in vivo in live animals.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Drug Discovery World

JANUARY 21, 2024

Advances in this area are having a positive effect on both the commercial success of drug discovery and development organisations, as well as benefitting the health and wellbeing of the global population. Technology plays multiple roles in all stages of vaccine development,” says Kanekiyo. “It

Protein 52

Protein Vaccination Vaccine Development 52

pharmaphorum

JANUARY 29, 2021

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. They wanted someone who had lots of experience in drug development, was a molecular biologist, and was stubborn enough to take on CRISPR!” billion in funding.

Gene Editing 141

Gene Editing Gene Gene Therapy In-Vivo 141

Drug Discovery World

SEPTEMBER 1, 2023

In the new study, led by scientists at The Institute of Cancer Research and published in Nature Communications , researchers identify a new cellular role of a protein called EXD2 nuclease and, importantly, its role in the so-called ALT (alternative lengthening of telomeres) pathway.

Drugs 59

Drugs Protein Research DNA 59

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

XTalks

SEPTEMBER 2, 2021

The AlzoSure Predict prognostic biomarker Alzheimer’s blood test detects levels of an unfolded conformational variant of the p53 protein in the blood using a proprietary antibody called U-p53AZ. It is known as the “guardian of the genome” given its central role in the DNA damage response. p53 in Alzheimer’s.

Protein 105

Protein DNA Antibody Genome 105

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

JUNE 5, 2023

New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. The discussion answered three main questions: What is the new direction for the company? How to improve its pipeline?

Genome 52

Genome Genomics Life Science Genetics 52

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Drug Discovery World

FEBRUARY 13, 2023

Using AI, researchers at Chalmers University of Technology, Sweden succeeded in designing synthetic DNA that controls the cells’ protein production. While companies make these commitments and partner for a better future, others shared successes in 2022.

Genome 52

Genome Genomics Life Science Drugs 52

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

FEBRUARY 6, 2024

From finding potential active substances and identifying novel targets, to simulating how drugs will function in the human body and optimising laboratory workflows, digital technologies are having a significant impact on drug discovery and development. The company’s platform evaluated more than 11.4

Marketing 69

Marketing Medicine Genome Genomics 69

Drug Discovery World

AUGUST 16, 2023

Additionally, patients whose cancer has spread but who have not yet received chemotherapy, and whose primary tumours have markers of faults in genes linked to DNA repair pathways, tend to respond better to carboplatin. “Our findings paint a complex picture – with many, dynamic factors driving how tumours respond to treatment.”

Genetics 52

Genetics Gene Hormones RNA 52

The Pharma Data

JUNE 7, 2023

a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.

Gene Therapy 40

Gene Therapy Gene Gene Editing RNA 40

Drug Discovery World

APRIL 17, 2024

JMB: Regulatory RNAs (or regRNAS) are molecules that directly control the expression of nearby protein-coding genes. Increasing gene expression via protein replacement or gene therapy has been shown to have limitations and drawbacks. JMB: Hundreds of genetic diseases involve a missing or deficient protein and/or enzyme.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

XTalks

NOVEMBER 30, 2023

Global entities such as the WHO, the Global Fund and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have developed comprehensive strategies aligned with Sustainable Development Goal (SDG) target 3.3, These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology.

Gene 83

Gene Immune Response Manufacturing Gene Therapy 83

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

MARCH 10, 2021

Cancer is a perennial fear for therapies that involve altering DNA in cells, because of the risk that the viruses used to deliver genes into patient cells could inadvertently lodge in the wrong place on a chromosome, triggering a mutation or disrupting a mechanism that guards against a cell becoming cancerous.

Gene Therapy 52

Gene Therapy Gene Trials Gene Expression 52

Drug Discovery World

JULY 17, 2024

Most NDDs are thought to be genetic and caused by changes to DNA, however, to date, around 60% of individuals with these conditions do not know the specific DNA change that causes their disorder. The findings, published in Nature , offer the first step in longed-for hope for the development of a treatment in the future.

Genetics 52

Genetics Genome Project Genome Genomics 52